HER-2 Positive Breast Cancer Market in the US 2015-2019
Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer. Analysts forecast the HER-2 Positive Breast Cancer market in US to grow at a CAGR of 12.65 percent over the period 2014-2019. Read more details @ http://www.bigmarketresearch.com/her-2-positive-breast-cancer-in-the-us-2015-2019-market
Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.
Analysts forecast the HER-2 Positive Breast Cancer market in US to grow at a CAGR of 12.65 percent over the period 2014-2019.
Read more details @ http://www.bigmarketresearch.com/her-2-positive-breast-cancer-in-the-us-2015-2019-market
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Top 10 Diabetes<br />
Care Technologies,<br />
Devices and<br />
<strong>HER</strong>-2 <strong>Positive</strong> <strong>Breast</strong><br />
Therapeutics<br />
<strong>Cancer</strong> <strong>Market</strong> <strong>in</strong> <strong>the</strong><br />
<strong>Market</strong>s <strong>US</strong> <strong>2015</strong>-<strong>2019</strong><br />
- Growth, Global Share,<br />
Industry Overview, Analysis,<br />
Trends Opportunities and<br />
Forecast 2012 - 2020
Description<br />
Report Overview<br />
About <strong>HER</strong>-2 <strong>Positive</strong> <strong>Breast</strong> <strong>Cancer</strong><br />
<strong>Breast</strong> cancer is characterized by uncontrolled growth of cancerous cells <strong>in</strong> <strong>the</strong><br />
breast. It occurs <strong>in</strong> both males and females, however, <strong>the</strong> <strong>in</strong>cidence of breast<br />
cancer <strong>in</strong> males is rare. Histologically, breast cancer can be classified <strong>in</strong>to ductal<br />
carc<strong>in</strong>oma, lobular carc<strong>in</strong>oma, nipple cancer, and o<strong>the</strong>r undifferentiated carc<strong>in</strong>oma.<br />
<strong>Breast</strong> cancer is <strong>the</strong> second most common form of cancer <strong>in</strong> women. <strong>HER</strong>-2 is a<br />
prote<strong>in</strong> that affects <strong>the</strong> growth of malignant cells and is usually found on <strong>the</strong><br />
surface of normal breast cells. Sometimes, a large number of <strong>HER</strong>-2 receptors are<br />
found on <strong>the</strong> surface of breast cancer cells. These <strong>HER</strong>-2 receptors are<br />
responsible for stimulat<strong>in</strong>g <strong>the</strong> growth and division of malignant cancerous cells.<br />
This condition is <strong>the</strong>refore known as <strong>HER</strong>-2 positive breast cancer. <strong>HER</strong>-2 positive<br />
breast cancers have a tendency to spread and metastasize more rapidly than<br />
<strong>HER</strong>-2 negative breast cancers.<br />
Analysts forecast <strong>the</strong> <strong>HER</strong>-2 <strong>Positive</strong> <strong>Breast</strong> <strong>Cancer</strong> market <strong>in</strong> <strong>US</strong> to grow at a<br />
CAGR of 12.65 percent over <strong>the</strong> period 2014-<strong>2019</strong>.<br />
Read more details @ http://www.bigmarketresearch.com/her-2-positivebreast-cancer-<strong>in</strong>-<strong>the</strong>-us-<strong>2015</strong>-<strong>2019</strong>-market<br />
@Bigmarketresearch
Description<br />
Report Overview<br />
This report covers <strong>the</strong> present scenario and <strong>the</strong> growth prospects of <strong>the</strong> <strong>HER</strong>-2<br />
<strong>Positive</strong> <strong>Breast</strong> <strong>Cancer</strong> market <strong>in</strong> <strong>the</strong> <strong>US</strong> for <strong>the</strong> period <strong>2015</strong>-<strong>2019</strong>. To calculate <strong>the</strong><br />
market size, <strong>the</strong> report considers revenue generated through <strong>the</strong> sales of targeted<br />
<strong>the</strong>rapeutics and chemo<strong>the</strong>rapeutics used <strong>in</strong> <strong>the</strong> management of <strong>HER</strong>-2 positive<br />
breast cancer patients.<br />
The report also presents <strong>the</strong> vendor landscape and a correspond<strong>in</strong>g detailed<br />
analysis of <strong>the</strong> top vendors <strong>in</strong> <strong>the</strong> <strong>HER</strong>-2 <strong>Positive</strong> <strong>Breast</strong> <strong>Cancer</strong> market <strong>in</strong> <strong>the</strong> <strong>US</strong>.<br />
In addition, it discusses <strong>the</strong> major drivers that <strong>in</strong>fluence <strong>the</strong> growth of <strong>the</strong> market. It<br />
also outl<strong>in</strong>es <strong>the</strong> challenges faced by <strong>the</strong> vendors and <strong>the</strong> market at large, as well<br />
as <strong>the</strong> key trends that are emerg<strong>in</strong>g <strong>in</strong> <strong>the</strong> market.<br />
<strong>HER</strong>-2 <strong>Positive</strong> <strong>Breast</strong> <strong>Cancer</strong> <strong>Market</strong> <strong>in</strong> <strong>US</strong> <strong>2015</strong>-<strong>2019</strong>, has been prepared based<br />
on an <strong>in</strong>-depth market analysis with <strong>in</strong>puts from <strong>in</strong>dustry experts. The report covers<br />
<strong>the</strong> market landscape of <strong>the</strong> <strong>HER</strong>-2 <strong>Positive</strong> <strong>Breast</strong> <strong>Cancer</strong> market <strong>in</strong> <strong>the</strong> <strong>US</strong> and<br />
its growth prospects over <strong>the</strong> com<strong>in</strong>g years. The report also <strong>in</strong>cludes a discussion<br />
of <strong>the</strong> key vendors operat<strong>in</strong>g <strong>in</strong> this market.<br />
@Bigmarketresearch
Description<br />
Report Overview<br />
Key Vendors<br />
• Celgene<br />
• F. Hoffmann-La Roche<br />
• GlaxoSmithKl<strong>in</strong>e<br />
• Novartis<br />
• Sanofi<br />
O<strong>the</strong>r Prom<strong>in</strong>ent Vendors<br />
• Bristol-Myers Squibb<br />
• DARA BioSciences<br />
• Eisai<br />
• Hospira<br />
• Pfizer<br />
• ProStrakan<br />
• Sun Pharmaceutical Industries<br />
• Teva Pharmaceutical<br />
@Bigmarketresearch
Description<br />
Report Overview<br />
<strong>Market</strong> Driver<br />
• Increase <strong>in</strong> Population of <strong>Breast</strong> <strong>Cancer</strong> Patients<br />
• For a full, detailed list, view our report<br />
<strong>Market</strong> Challenge<br />
• Poor Diagnosis and Screen<strong>in</strong>g<br />
• For a full, detailed list, view our report<br />
<strong>Market</strong> Trend<br />
• Increase <strong>in</strong> Awareness<br />
• For a full, detailed list, view our report<br />
Enquire About Report @ http://www.bigmarketresearch.com/reportenquiry/183633<br />
@Bigmarketresearch
Table Of Contents<br />
Table Of Content<br />
01. Executive Summary<br />
02. List of Abbreviations<br />
03. Scope of <strong>the</strong> Report<br />
04. <strong>Market</strong> Research Methodology<br />
05. Introduction<br />
06. Disease Overview<br />
07. <strong>Market</strong> Landscape<br />
08. <strong>Market</strong> Segmentation by Type of Therapy<br />
09.9 <strong>Market</strong> Segmentation by Molecule Type<br />
10 <strong>Market</strong> Segmentation by Route of Adm<strong>in</strong>istration<br />
11 Buy<strong>in</strong>g Criteria<br />
12 <strong>Market</strong> Growth Drivers<br />
13 Drivers and <strong>the</strong>ir Impact<br />
14 <strong>Market</strong> Challenges<br />
15 Impact of Drivers and Challenges<br />
16 <strong>Market</strong> Trends<br />
17 Trends and <strong>the</strong>ir Impact<br />
18 Vendor Landscape<br />
19 Key Vendor Analysis<br />
20 O<strong>the</strong>r Reports <strong>in</strong> this Series<br />
@Bigmarketresearch
Get Full Information<br />
At:<br />
http://www.bigmarketresearch.com<br />
/her-2-positive-breast-cancer-<strong>in</strong><strong>the</strong>-us-<strong>2015</strong>-<strong>2019</strong>-market
Change language